<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362825">
  <stage>Registered</stage>
  <submitdate>16/02/2013</submitdate>
  <approvaldate>21/02/2013</approvaldate>
  <actrnumber>ACTRN12613000206729</actrnumber>
  <trial_identification>
    <studytitle>A Randomized, Multi-Centre, Open-Label Study of Neo-adjuvant Taxanes and Capecitabine(TX) versus Taxanes and Anthracycline(TA) for Breast Cancer</studytitle>
    <scientifictitle>A Randomized, Multi-Centre, Open-Label Study: Comparision  of the efficacy and safety of Neo-adjuvant Taxanes and Capecitabine(TX) versus Taxanes and Anthracycline(TA) in Patients with  Breast Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast cancer</healthcondition>
    <healthcondition>Neoadjuvant chemotherpy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The patients with breast cancer are randomly assigned to one of two groups, receiving taxanes and capecitabine(TX) or taxanes and anthracycline(TA) regimen in neoadjuvant setting.  The treatment response would be evaluated after the completion of two cycles. In compelte response , partial response, and stable patients, the therapy will be continued to four cycles , but patients with progressive lesions will be excluded(individualized therapy will be considered). After four cycle chemotherapy, surgery  will be carried out and pathological response will be assessed. The specific surgery type, breast conserving surgery or modified radical mastectomy, will be dependent on individual patient.
1. TX arm: paclitaxel 175mg/m2, or docetaxel 75 mg/m2, introvenous, once every 3 weeks, combined with Capecitabine  1000mg/m2, oral, twice every day for 14 days,every 3 weeks.
2. TA arm: paclitaxel 175mg/m2, or docetaxel 75 mg/m2, introvenous, once every 3 weeks, combined with epirubicin 75mg/m2, introvenous, once every 3 weeks.</interventions>
    <comparator>TA regimen</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pathological complete response (pCR) rate (pCR is defined as no residual cancer at histologic examination
)</outcome>
      <timepoint>after the surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>the adverse effect of the chemotherapy: 
1. Common toxic reaction is assessed according to National Cancer Institution (NCI) Toxicity Criteria 
2. Hand-foot sydrome (HFS) is recorded according to the HFS grading scale (online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796406/table/T1/)</outcome>
      <timepoint>One week after every cycle and 3 months after the completion of the chemotherapy </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.Histological comfirmed breast cancer
2.Non-special type breast cancer
2.With at least one measurable lesion
3.Without distant metastasis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.Without any contradiction of chemotherapy or the drug concerned
2.ECOG score &gt; 1
3.No systemic anti-cancer therapy before</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by phone , and by computer in some centers
</concealment>
    <sequence>1. Randomized block design is used
2. The sequence was created by a computer software ( SAS)
</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/09/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peking University People's Hospital Breast Center</primarysponsorname>
    <primarysponsoraddress>Peking University People's Hospital Breast Cancer Center,No 11 Xizhimen South Street,Beijing 100044</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Chinese Anti-Cancer Association Committee of Breast Cancer Society</fundingname>
      <fundingaddress>5-A-10,Lanyuan Road, Huayuan Industrial Park, Tianjin 300000</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Chinese Anti-Cancer association Committee of Breast Cancer Society</sponsorname>
      <sponsoraddress>5-A-10,Lanyuan Road, Huayuan Industrial Park, Tianjin 300000</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>People's Liberation Army General Hospital</othercollaboratorname>
      <othercollaboratoraddress>No 28 Fuxing Lu, Haidian District,Beijing 100000</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Peking University First Hospital</othercollaboratorname>
      <othercollaboratoraddress>No 8  Xishiku Street, West City District, Beijing 100000</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Beijing Tongren Hospital</othercollaboratorname>
      <othercollaboratoraddress>No 2 Chongwenmennei Street, Dongcheng District, Beijing 100730 </othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Beijing Friendship Hospital</othercollaboratorname>
      <othercollaboratoraddress>No 95 Yong'an Lu, Xuanwu District, Beijing 100000</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>307 Hospital of PLA</othercollaboratorname>
      <othercollaboratoraddress>No 8 East Avenue , Fengtai District, Bejing 100000</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Beijing Shijitan Hospital</othercollaboratorname>
      <othercollaboratoraddress>No.10, Tieyi Road, Yangfangdian, Haidian District, Beijing 100000</othercollaboratoraddress>
      <othercollaboratorcountry>China</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized clinical trial comparing  combination of taxanes and capecitabine (TX) versus the combination of taxanes and anthracycline (TA) in neoadjuvant setting in patients with stage II-III breast cancer. The first end point is treatment response (pCR rate). And the adverse effect related to the preoperative cytotoxic therapy is assessed.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peking University People's Hospital Ethics Committee</ethicname>
      <ethicaddress>Peking University People's Hospital,No 11 Xizhimen South Street,Beijing 100044</ethicaddress>
      <ethicapprovaldate>27/06/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Shu Wang</name>
      <address>Peking University People's Hospital Breast Center,No11 Xizhimen South Street, Beijing 10044</address>
      <phone>+86,010,88324011</phone>
      <fax>+86,010,88324013</fax>
      <email>wangshu@pkuph.edu.cn</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Houpu Yang</name>
      <address>Peking University People's Hospital Breast Center,No11 Xizhimen South Street, Beijing 10044</address>
      <phone>+86,010,88324010</phone>
      <fax>+86,010,88324013</fax>
      <email>vulcan@bjmu.edu.cn</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Houpu Yang</name>
      <address>Peking University People's Hospital Breast Center,No11 Xizhimen South Street, Beijing 10044</address>
      <phone>+86,010,88324010</phone>
      <fax>+86,010,88324011</fax>
      <email>vulcan@bjmu.edu.cn</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Deqi Yang</name>
      <address>Peking University People's Hospital Breast Center,No11 Xizhimen South Street, Beijing 10044</address>
      <phone>+86,010,88324010</phone>
      <fax />
      <email>yangdeqi@pkuph.edu.cn</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>